Lanean...
The development of antibody –based immunotherapy with (EMD-273063) Hu14.18-IL2 in melanoma and neuroblastoma
Patients with high risk melanoma and neuroblastoma frequently recur despite surgical resection and appropriate adjuvant therapies. Immunotherapy with the immunocytokine, hu14.18-IL2, was developed via fusion of two molecules of IL2 to the monoclonal antibody, 14.18, that recognizes GD2, expressed on...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2009
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2952306/ https://ncbi.nlm.nih.gov/pubmed/19548853 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/13543780903048911 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|